Kera Capital Partners Inc. acquired a new stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 3,298 shares of the medical equipment provider's stock, valued at approximately $354,000.
Several other institutional investors also recently bought and sold shares of the company. AG2R LA Mondiale Gestion D Actifs purchased a new stake in Boston Scientific during the 1st quarter valued at about $5,773,000. Swedbank AB lifted its stake in Boston Scientific by 2.8% during the 1st quarter. Swedbank AB now owns 1,314,230 shares of the medical equipment provider's stock valued at $132,580,000 after acquiring an additional 35,300 shares during the period. 1248 Management LLC purchased a new stake in shares of Boston Scientific during the 1st quarter valued at about $35,000. Modern Wealth Management LLC boosted its holdings in shares of Boston Scientific by 7.9% during the 1st quarter. Modern Wealth Management LLC now owns 2,974 shares of the medical equipment provider's stock valued at $300,000 after acquiring an additional 218 shares during the last quarter. Finally, Birmingham Capital Management Co. Inc. AL purchased a new stake in shares of Boston Scientific during the 1st quarter valued at about $202,000. 89.07% of the stock is owned by hedge funds and other institutional investors.
Boston Scientific Price Performance
NYSE BSX opened at $102.71 on Friday. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50. The stock has a market cap of $152.19 billion, a price-to-earnings ratio of 61.14, a PEG ratio of 2.51 and a beta of 0.65. The company's 50 day moving average is $104.86 and its two-hundred day moving average is $102.26. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.
Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. During the same quarter last year, the business earned $0.62 EPS. The firm's revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.
Insider Activity
In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares of the company's stock, valued at $1,959,328.37. This trade represents a 17.79% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $105.43, for a total transaction of $5,271,500.00. Following the sale, the executive vice president directly owned 178,342 shares of the company's stock, valued at approximately $18,802,597.06. This trade represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock worth $18,397,457 in the last quarter. 0.50% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $121.00 price target on shares of Boston Scientific in a report on Thursday. UBS Group raised their price target on shares of Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a report on Thursday, July 24th. Robert W. Baird raised their price target on shares of Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Leerink Partnrs raised shares of Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Finally, Oppenheimer raised shares of Boston Scientific from a "market perform" rating to an "outperform" rating and raised their price target for the company from $118.00 to $125.00 in a report on Monday, September 8th. Three analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $118.04.
View Our Latest Report on Boston Scientific
About Boston Scientific
(
Free Report)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Boston Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.
While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
